Small molecule · developed by Spero Therapeutics
SPR720 is an oral small-molecule drug administered in capsule form. It is being studied in healthy volunteers and in patients with nontuberculous mycobacterial pulmonary disease, including Mycobacterium avium complex infection.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05496374 | Phase 2 | Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) | Completed | SPRO |
| NCT04553406 | Phase 2 | Mycobacterium Avium Complex | Terminated | SPRO |
| NCT03796910 | Phase 1 | Healthy Volunteers | Completed | SPRO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Healthy VolunteersMycobacterium Avium ComplexNon-tuberculous Mycobacterium Pulmonary DiseaseNontuberculous Mycobacterial Pulmonary Disease (NTM-PD)
Updated Oct 3, 2026. Something wrong or missing? Report it on the SPRO page.
See SPRO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SPRO catalysts and pipeline →